Investment Banking case studies, worked step by step
- Cases
- 100
- Traced to a firm
- 55
- Topics
- 12
- Hard
- 30
Topic
Showing 11–20 of 30 · filtered from 100Clear filters
- 032Paper LBO: three years in, the sponsor can relever the company and pay itself a dividend. Compare the money multiple and the IRR with and without the recap.Moelis & CompanyNew York · 2023
- 036A buyer can acquire a brand business as an asset deal and step up the tax basis, or as a share deal and inherit the old basis. How much is the asset deal worth to the buyer, and how should the seller's extra tax be shared?Morgan StanleyHong Kong · 2025
- 044A company receives an unsolicited cash offer at a 30% premium. Its own DCF range brackets the offer, and a white knight might pay more in stock with some risk of failing. Should the board accept, reject or pursue the white knight?Elite boutique IBCorporate development
- 048A property company offers to swap notes due in a year for fewer, longer, second lien notes, conditional on 90% taking it. Value the offer to a holder who exchanges and to one who holds out, and explain the holdout problem.Houlihan LokeyNew York · 2025
- 056Compare an AI model developer burning cash to grow 150% a year with a mature, highly profitable enterprise software company. Which multiple would you use for each, what drives value, and where would you look for growth?EvercoreNew York · 2026
- 058Saptak Holdings owns 80% of a power generator with its own debt and all of a small trading arm, and owes notes at the holding company. What do the holdco noteholders recover in a liquidation, and how do the consolidated accounts overstate their protection?Moelis & CompanyNew York · 2025
- 060How would you value a company with negative cash flows? Value Zyvora Mobility, a fast-growing loss-maker, with an eight-year DCF and an exit multiple, and show where the value comes from.Credit SuisseNew York · 2025
- 061Shunyak Data Centres has 100 MW operating and 150 MW under construction. How would you value the operating and development portfolios, and what risk sits in each?LazardNew York · 2026
- 063Hemvik Pharma can borrow Rs 1,000 crore at 9% or issue a 2% convertible at a 30% premium. Compare EPS under each, find the share price at which conversion makes sense, and say what Hemvik is really selling.Equity capital marketsDebt capital markets
- 064A CLO's mezzanine overcollateralisation test fails after defaults. Does it fail, by how much, and how much interest is diverted away from the equity to cure it?NomuraNew York · 2026
Company names and figures are illustrative.
